Ensorcell (ensorcell.bio), a US-based company focused on reimaging life science tools and solutions for the biopharmaceutical industry, announced on Tuesday the appointments of Geoff Hodge and Amy Teachout to its senior leadership team.
Hodge is named head of Technology, responsible for accelerating high impact innovation across the company's technology and product development initiatives. He brings decades of experience spanning biopharmaceutical research, development, manufacturing, and technology leadership from his experience as co-founder of Xcellerex, CEO of SOTIO Biotech, and CTO of Unum Therapeutics. His focus at Ensorcell will be on translating novel concepts into scalable solutions that help partners advance programs efficiently from development through manufacturing.
Teachout has been appointed head of Customer Excellence, with responsibility for ensuring seamless, high-quality customer care across the full client engagement lifecycle. She brings extensive experience in program leadership, commercialisation support, logistics, and customer care.
Jeff Goldman, Ensorcell general manager, said: "Geoff and Amy bring deep industry expertise and complementary leadership strengths. Geoff's focus on accelerating high-impact breakthroughs and Amy's leadership in customer excellence directly support Ensorcell's mission to deliver meaningful, reliable outcomes for our biopharma partners."
BioMarin completes Alesta Therapeutics acquisition
BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline
AstraZeneca completes global licence agreement for Zegfrovy
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
UCB agrees with US government to lower medicine costs and strengthen US manufacturing
Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis
Lilly to acquire Merida Biosciences in USD2.875bn deal
Harvest Integrated Research Organization signs MoU with Differentia Biotech
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Zambon receives European Commission approval for Hopledo in Parkinson's disease
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
SpyGlass Pharma opens new HQ in Irvine, California
AusperBio completes USD120m Series C financing to advance AHB-137